Clinical Trial Update: Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and effectiveness of the oral HIV entry inhibitor Vicriviroc in HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Vicriviroc (MK-7690)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED